Advertisement
Canada markets open in 3 hours 36 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7327
    +0.0003 (+0.05%)
     

  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     

  • Bitcoin CAD

    87,935.30
    +718.17 (+0.82%)
     

  • CMC Crypto 200

    1,392.53
    -4.01 (-0.29%)
     

  • GOLD FUTURES

    2,360.50
    +18.00 (+0.77%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,733.50
    +166.00 (+0.94%)
     

  • VOLATILITY

    15.64
    +0.27 (+1.76%)
     

  • FTSE

    8,117.40
    +38.54 (+0.48%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6821
    0.0000 (0.00%)
     

Teva Expects a Fall in Its Expenses and Cost Base in Fiscal 2018

Sarah Collins
Updated
Teva Expects a Fall in Its Expenses and Cost Base in Fiscal 2018

Recently, Teva Pharmaceutical (TEVA) has witnessed trouble in its business due to a number of company-specific and macroeconomic factors. The Copaxone sales decline due to generic competition, the pricing pressures in the market, and the impairments recently recorded by Teva are among the major factors triggering the company’s restructuring to recuperate the decline in its sales and earnings. For more information, read The Key Challenges Teva Pharmaceutical Is Facing.

Continue reading